Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns
| Status: | Completed |
|---|---|
| Conditions: | Depression, Depression |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 25 - 55 |
| Updated: | 10/8/2017 |
| Start Date: | April 2014 |
| End Date: | November 2016 |
The objectives of this project are to determine if the bioavailability and release pattern of
bupropion HCl products differ and if the genotype of the metabolic enzymes affects the
saturation of intestinal enzymes with different dose strengths within one product line.
Findings from this project will help the FDA Center for Drug Evaluation and Research's (CDER)
Office of Generic Drugs improve policy development and review practice in the future for
similar products, e.g. extended release oral drug products being metabolized in the gut wall
and having multiple strengths.
Aim 1: To compare the pharmacokinetics of bupropion and its metabolites in plasma in healthy
individuals when they ingest different strengths of bupropion (75-300 mg) with variable
release profiles (IR vs XL vs SR) in GI tract.
Working hypothesis: Variation in release rate and mechanism of bupropion formulations in
gastrointestinal (GI) tract will impact metabolism and saturation of bupropion in GI tract,
which will generate different concentration of bupropion and its metabolites in plasma.
Aim 2: To investigate pharmacogenomics of CYP 2B6 that influences metabolism, saturation, and
pharmacokinetics of bupropion
Working hypothesis: The gain of function of CYP2B6 variants (allele *4 and *22) in patients
will increase the metabolism of bupropion in the GI tract and liver, reduce both local
concentration and plasma concentration of bupropion, and thus cause non-bioequivalence when
bupropion is released earlier in GI tract
bupropion HCl products differ and if the genotype of the metabolic enzymes affects the
saturation of intestinal enzymes with different dose strengths within one product line.
Findings from this project will help the FDA Center for Drug Evaluation and Research's (CDER)
Office of Generic Drugs improve policy development and review practice in the future for
similar products, e.g. extended release oral drug products being metabolized in the gut wall
and having multiple strengths.
Aim 1: To compare the pharmacokinetics of bupropion and its metabolites in plasma in healthy
individuals when they ingest different strengths of bupropion (75-300 mg) with variable
release profiles (IR vs XL vs SR) in GI tract.
Working hypothesis: Variation in release rate and mechanism of bupropion formulations in
gastrointestinal (GI) tract will impact metabolism and saturation of bupropion in GI tract,
which will generate different concentration of bupropion and its metabolites in plasma.
Aim 2: To investigate pharmacogenomics of CYP 2B6 that influences metabolism, saturation, and
pharmacokinetics of bupropion
Working hypothesis: The gain of function of CYP2B6 variants (allele *4 and *22) in patients
will increase the metabolism of bupropion in the GI tract and liver, reduce both local
concentration and plasma concentration of bupropion, and thus cause non-bioequivalence when
bupropion is released earlier in GI tract
Inclusion Criteria:
- Healthy volunteers 25 to 55 years old.
- Volunteers have a Body Mass Index (BMI), calculated from the ratio of height and
weight, within a range of 18.5 to 35.
- Willing to be medication and supplement free 2 weeks prior to beginning study, and
throughout the study. All forms of birth control are okay.
Exclusion Criteria:
- Individuals unwilling or unable to comply with the study protocol (e.g. unable to
remain medication or supplement free during the study).
- Individuals unwilling or unable to take bupropion or have an allergy to bupropion
- Any medical or surgical conditions which might significantly alter bupropion
absorption (e.g., history of malabsorption, liver disease, gastric bypass surgery )
- Individuals with a history of psychiatric or neurological illness, including seizure
disorders
- Nicotine dependence
- Alcohol dependence
- Pregnant or nursing women
We found this trial at
1
site
University of Michigan The University of Michigan was founded in 1817 as one of the...
Click here to add this to my saved trials
